Drug Profile
Research programme: immune mobilising mTCR based therapeutics - GlaxoSmithKline/Immunocore
Alternative Names: ImmTAC based therapeutics - ImmunocoreLatest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Immunocore
- Developer GSK; Immunocore
- Class Bispecific antibodies; Immunoproteins; Immunotherapies
- Mechanism of Action Immunomodulators; T-cell receptor antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer